Drug intelligence / Profile preview

Ningxia Medical Univ. Keap1 compound 19

Development stage: Preclinical
Lead developer: Ningxia Medical University

Overview

Ningxia Medical Univ. Keap1 compound 19: sourced facts only. name: "Structure-activity relationship studies identified compound 19 as the most potent, with a KD2 of 42.2 nM against Keap1." [PMID:39232343]; target: "Structure-activity relationship studies identified compound 19 as the most potent, with a KD2 of 42.2 nM against Keap1." [PMID:39232343]; developer: "Key Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area (Ningxia Medical University), Ministry of Education, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China." [PMID:39232343]; stage: "Compound 19 effectively alleviated symptoms at doses of 15 mg/kg for ALI injury." [PMID:39232343]

Targets

KEAP1 (Kelch-like ECH-associated protein 1)

Beyond the preview

Go deeper on Ningxia Medical Univ. Keap1 compound 19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ningxia Medical Univ. Keap1 compound 19.